Cobham And Oxshott PCN

Registered patients aged 65+ reach 21.6%, alongside 600 catchment care home beds

Of 20,473 registered patients, 21.6% (4,419) are aged 65+, above Elmbridge (17.9%), NHS Surrey Heartlands Integrated Care Board (18.8%) and England (17.9%). The catchment contains 11 care homes with 600 beds. ONS-led list growth to 2030 is projected at 1.3%, trailing Elmbridge (3.6%), the ICB (4.9%) and England (2.3%). Residential Census estimates show 86.5% White (Elmbridge 86.1%, ICB 85.3%, England 81.1%), 6.1% Asian / Asian British, and 13.5% ethnic minorities. Catchment beds do not verify PCN registration, and the projection methodology is unverified.

Average deprivation is low with zero registered Core20 patients across both practices

The PCN has an average IMD decile of 8.8, reflecting lower relative deprivation than England (5.5 decile), Elmbridge (8.6 decile), and the ICB (7.9 decile). Recorded Core20 registered patients stand at 0.0% across both Cobham Health Centre (IMD decile 8.8) and Oxshott Medical Practice (IMD decile 9.3), compared with 21.0% in England and 0.8% in the ICB. However, 2 of 14 associated LSOAs fall in national IMD decile 2. LSOA residents and registered lists use different bases.

PLUS groups and inclusion health

The learning disability register records 64 patients (0.3%), matching Elmbridge (0.3%) but below the ICB (0.5%) and England (0.6%). The severe mental illness register records 120 patients (0.6%), below Elmbridge (0.7%), the ICB (0.8%) and England (1.0%). Applying Elmbridge's 7.4% Census unpaid-care rate gives a modelled ceiling of 1,515 carers. Elmbridge recorded 12 rough sleepers in autumn 2025.

Severe mental illness: physical health checks

Severe mental illness prevalence is 0.6% (120 patients) against 1.0% in England. Recorded blood pressure checks reach 89.0% and BMI checks reach 84.4%. Missing check elements mean completed annual physical checks cannot be confirmed across the register.

Clinical focus: hypertension and lipids

Hypertension case-finding and control

Recorded hypertension prevalence is 11.3% (2,466 patients), below Elmbridge at 12.6%, NHS Surrey Heartlands Integrated Care Board at 14.3% and England at 15.2%, though the implied denominator of 21,727 does not match the registered list. Recent blood pressure checks stand at 86.8%, behind Elmbridge at 88.1%, the ICB at 89.6% and England at 90.0%. However, clinical management shows notable gains: treatment to target is 71.4%, in line with the ICB (71.4%) and above England (70.3%). Patients aged under 80 controlled to threshold reached 65.7% after a +11.6% three-year rise (England +3.2%), and control in those aged 80+ reached 81.4% following a +10.1% rise (England +2.2%). Hypertension control is comparatively strong once diagnosed, but lower recorded prevalence and trailing recent blood.

Lipids and statins

Patients with QRISK ≥ 20% on lipid-lowering therapy reach 55.3% (England 63.6%), rising +3.2% over three years (England +6.2%). Chronic kidney disease lipid coverage is 63.7% (England 70.3%). Fewer at-risk patients receive lipid-lowering therapy than England rates imply, indicating a need for high-risk recall.

In 2026, lipid-regulating drugs cost £2.50 per item (England £1.86), representing £12,456 more than at England's unit cost across 19,463 items. Across 27,572 cardiovascular system items in 2025, cost per item was £6.46 (England £3.33), or £86,300 more than at England's unit cost. Higher unit costs across cardiovascular and lipid-regulating prescribing indicate potential opportunities for formulary review.

Clinical focus: respiratory, cancer register and children

Respiratory

Asthma prevalence is 4.7% (963 patients) against 6.6% in England, and COPD prevalence is 0.8% (176 patients) against 1.9%. Over 2023 to 2025, annual review rates fell 14.5% for COPD (England +2.8%) to 77.3% and 6.5% for asthma (England +4.4%) to 62.2%, trailing the ICB (65.6%). Oxshott Medical Practice recorded a lower asthma review rate (55.2%) than Cobham Health Centre (66.5%). Lower reviews leave about 360 asthma patients unreviewed, so prioritising recall capacity may prevent acute escalations.

Cancer register and children's immunisation

Cancer prevalence is 5.3% (1,154 patients), above England (3.8%). In Q1 2025/26 childhood immunisation, age-5 pre-school 4-in-1 booster coverage is 83.0%, below the 95.0% target by 12 pp, while MMR dose 2 is 89.4%. At Cobham Health Centre, an 80.8% MMR2 rate leaves a 15.4 pp gap from MMR1 (96.2%), whereas Oxshott Medical Practice reached 100.0%. Targeting pre-school recall at Cobham Health Centre is the priority to close booster shortfalls.

Early cancer diagnosis

In 2022, 61.4% of staged cancers across NHS Surrey Heartlands ICB were diagnosed at stage 1 or 2 (England 55.3%), with known stage recorded in 67.7% of registered cancers (England 67.0%). This leaves the system below the national 75.0% ambition by 13.6 pp, representing about 650 extra early-stage cases required annually across the ICB. Primary care screening coverage shows local shortfalls: breast screening coverage (aged 53 to 70) is 66.7% (ICB 71.2%, England 69.9%) and cervical screening (aged 25 to 49) is 67.8% (ICB 69.3%, England 66.8%), dipping to 64.1% and 66.3% respectively at Cobham Health Centre. These ICB figures reflect wider system staging rather than PCN performance.

Cancer waits, diagnostics and community services

Cancer waits and diagnostics, Jul 2026 (provisional)

In provisional July 2026 data, Epsom and St Helier University Hospitals NHS Trust achieved 86.8% on the 62-day referral to treatment standard, ahead of Ashford and St Peter's Hospitals NHS Foundation Trust (76.4%), Kingston and Richmond NHS Foundation Trust (75.3%), NHS Surrey and Sussex Integrated Care Board (71.5%) and England (71.2%), against the 85.0% standard. The trust reached 89.7% on 28-day faster diagnosis (standard 75.0%) and 99.2% on 31-day treatment (standard 96.0%). For all diagnostic tests, 6.8% waited 6+ weeks at the trust, below England (23.1%). These acute trust figures describe system pathways, not PCN performance.

Phone access diverges by 40.8 percentage points between the two constituent practices

In 2025/26, overall QOF achievement was 94.2% at Cobham Health Centre and 89.7% at Oxshott Medical Practice (England 92.5%). While both achieved high clinical scores (100.0% and 97.6%), vaccination and immunisation achievement diverged by 19.8 pp (49.3% vs 29.6%; England 55.2%). Overall personalised care adjustments were 10.7% at Cobham and 6.2% at Oxshott.

Ten of 25 tracked three-year trends trail England, led by falling respiratory reviews

Across 25 tracked three-year trends, 10 trail England. The widest lags are in annual chronic disease reviews: COPD reviews fell 14.5% over 2023 to 2025 (England +2.8%), asthma reviews fell 6.5% (England +4.4%), and heart failure reviews fell 1.4% (England +8.7%). Conversely, blood pressure control rose +11.6% for patients under 80 (England +3.2%) and +10.1% for those aged 80 and over (England +2.2%), alongside statin prescribing in diabetes (+8.0% vs England +2.1%). Falling reviews may reflect recall capacity, unverified locally; an audit would test it.

What the data can't tell us: gaps and local assets

Options for the PCN

Each option in full

Provenance and audit trail

Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.

Data sources

Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.

Methods, data-quality notes and limitations